## Judge Dismisses Landmark Lawsuit Seeking Retraction of Controversial Paxil 'Study 329'
A judge has dismissed a high-stakes legal challenge that sought to force the scientific publisher Elsevier to retract the long-disputed 'Study 329,' a 2001 paper that concluded the antidepressant Paxil was safe and effective for adolescents. The lawsuit, filed under the D.C. Consumer Protection Procedures Act, argued that the continued publication of the study constituted a fraudulent commercial practice, misleading doctors and the public. This dismissal represents a significant setback for critics who have argued for over two decades that the flawed research has led to the unwarranted and potentially harmful prescription of the drug to youth.

The case was brought by attorney George W. Murgatroyd III against the American Academy of Child and Adolescent Psychiatry (AACAP), which owns the Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP), and its publisher, Elsevier. The legal action followed the journal's placement of an 'expression of concern' on the paper last October, a move that acknowledged the persistent scrutiny but stopped short of a full retraction. The core allegation was that the parties were profiting from the distribution of a study containing material misrepresentations of the clinical trial data.

The judge's ruling leaves the controversial paper officially standing in the scientific record, though heavily flagged. This outcome underscores the immense legal and institutional barriers to compelling the retraction of published research, even studies with a well-documented history of criticism. It maintains pressure on publishers and professional societies regarding their ethical responsibilities for the enduring scientific literature that continues to influence medical practice.
---
- **Source**: Retraction Watch
- **Sector**: The Lab
- **Tags**: Scientific Publishing, Pharmaceuticals, Legal Challenge, Research Ethics, Paxil
- **Credibility**: unverified
- **Published**: 2026-04-02 17:57:02
- **ID**: 47785
- **URL**: https://whisperx.ai/en/intel/47785